Enlivex (ENLV) Common Equity (2013 - 2025)
Enlivex (ENLV) posted quarterly Common Equity of $1.9 billion for Q4 2025, up 8102.76% year-over-year from $23.6 million in Q4 2024, and up 10968.86% quarter-over-quarter from $17.5 million in Q3 2025.
Enlivex (ENLV) Common Equity (2013 - 2025) Analysis & Trends
Enlivex's Common Equity history runs 13 years deep, the most recent figure standing at $1.9 billion for Q4 2025.
- In Q4 2025, Common Equity rose 8102.76% year-over-year to $1.9 billion; the TTM figure through Dec 2025 stood at $1.9 billion (up 8102.76% YoY), while the FY2025 annual figure was $1.9 billion, up 8102.76% from the prior year.
- Common Equity for Q4 2025 stood at $1.9 billion, up from $17.5 million in the prior quarter.
- The five-year high for Common Equity was $1.9 billion in Q4 2025, with the low at $17.5 million in Q3 2025.
- The 5-year median for Common Equity is $47.5 million (2023), against an average of $144.1 million.
- The sharpest annual moves came in 2021 and 2023: Common Equity soared 72846.77% in 2021, then sank 47.07% in 2023.
- Enlivex's Common Equity stood at $85.0 million in 2021, then sank by 33.16% to $56.8 million in 2022, then tumbled by 47.07% to $30.1 million in 2023, then retreated by 21.59% to $23.6 million in 2024, then soared by 8102.76% to $1.9 billion in 2025.
- Business Quant data shows ENLV's Common Equity at $1.9 billion in Q4 2025, $17.5 million in Q3 2025, and $19.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - | 1.93 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.93 Bn |
| Sep 30, 2025 | 17.48 Mn |
| Jun 30, 2025 | 19.05 Mn |
| Mar 31, 2025 | 20.63 Mn |
| Dec 31, 2024 | 23.59 Mn |
| Sep 30, 2024 | 26.59 Mn |
| Jun 30, 2024 | 28.56 Mn |
| Mar 31, 2024 | 26.85 Mn |
| Dec 31, 2023 | 30.08 Mn |
| Sep 30, 2023 | 38.78 Mn |
| Jun 30, 2023 | 44.34 Mn |
| Mar 31, 2023 | 50.57 Mn |
| Dec 31, 2022 | 56.84 Mn |
| Sep 30, 2022 | 63.27 Mn |
| Jun 30, 2022 | 68.49 Mn |
| Mar 31, 2022 | 77.65 Mn |
| Dec 31, 2021 | 85.04 Mn |
| Sep 30, 2021 | 88.08 Mn |
| Jun 30, 2021 | 90.21 Mn |
| Mar 31, 2021 | 90.61 Mn |